Actionable news
0
All posts from Actionable news
Actionable news in INO: Inovio Pharmaceuticals, Inc.,

GeneOne Life Science Announces Full Enrollment of First-In-Human Study of MERS Vaccine

SEOUL, South Korea, Aug. 08, 2016 (GLOBE NEWSWIRE) -- GeneOne Life Science Inc. (011000.KS) today announced that enrollment has been completed of the first-in-human clinical trial of the GLS-5300 vaccine for MERS (Middle East Respiratory Syndrome) with a total of 75 subjects. GeneOne Life Science and U.S.-based Inovio Pharmaceuticals (INO) are co-developing the vaccine. This phase I clinical trial is funded by the Walter Reed Army Institute of Research (WRAIR) and is being conducted at its Clinical Trials Center in Silver Spring, Md.

The MERS vaccine (GLS-5300) was designed as a SynCon® vaccine by Inovio and was manufactured by VGXI, Inc., which is GeneOne’s wholly owned subsidiary and located in the Woodlands, Texas.

Middle East Respiratory Syndrome is caused by a coronavirus that is related to the severe acute respiratory syndrome (SARS) virus that over 10 years ago infected more than 8,000 people, with a 10% death rate. There is no vaccine or effective treatment against MERS, which spreads from human to human. Since 2012, MERS has infected almost 1,500 people and killed about 600 (40%). In the summer of 2015, South Korea was the site for the largest outbreak outside of Saudi Arabia of this emergent global health concern with 186 people infected with 36 (20%) fatalities.

Mr. Young K. Park, CEO, GeneOne Life Science, said, “MERS cases are continuing in the Middle East and we are moving rapidly with our partners to test a MERS vaccine in the clinic because there is no vaccine or treatment for this virulent virus. The completion of enrollment is a major step forward in combatting a highly lethal infection that has triggered widespread outbreaks in the Middle East and Korea.

About Inovio Pharmaceuticals, Inc.

Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the...


More